This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
BP (BP.L) - Faces a first and heavy loss from its stake in Russia's Rosneft due to plummeting oil prices and a crumbling rouble, potentially forcing it to write down the value of its once-prized asset. Closing Price 401.95p (Reuters)
Carillion (CLLN.L) - Carillion has been selected by argent as preferred bidder to deliver three new prestigious buildings at king's cross regeneration project. Combined value of three buildings will be in excess of £100m. Construction will commence in later part of 2015 with completion scheduled during 2017. Closing price 323.20 (Reuters)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| AstraZeneca | AZN.L | 2.78% | 2.96% | 0.15% |
| Galliford Try | GFRD.L | -0.25% | 1.24% | -0.68% |
| Shire | SHP.L | 3.54% | 4.09% | 1.11% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research